[go: up one dir, main page]

TW200806284A - Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma - Google Patents

Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma

Info

Publication number
TW200806284A
TW200806284A TW096110518A TW96110518A TW200806284A TW 200806284 A TW200806284 A TW 200806284A TW 096110518 A TW096110518 A TW 096110518A TW 96110518 A TW96110518 A TW 96110518A TW 200806284 A TW200806284 A TW 200806284A
Authority
TW
Taiwan
Prior art keywords
glaucoma
treatment
ocular hypertension
hypertension control
prenyltransferase inhibitors
Prior art date
Application number
TW096110518A
Other languages
English (en)
Inventor
Allan R Shepard
Debra L Fleenor
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Publication of TW200806284A publication Critical patent/TW200806284A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW096110518A 2006-03-31 2007-03-27 Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma TW200806284A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78797106P 2006-03-31 2006-03-31

Publications (1)

Publication Number Publication Date
TW200806284A true TW200806284A (en) 2008-02-01

Family

ID=38230203

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096110518A TW200806284A (en) 2006-03-31 2007-03-27 Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma

Country Status (14)

Country Link
US (3) US20070232675A1 (zh)
EP (1) EP2001457A1 (zh)
JP (1) JP2009532377A (zh)
KR (1) KR20080111092A (zh)
CN (1) CN101410104A (zh)
AR (1) AR060186A1 (zh)
AU (1) AU2007234903B2 (zh)
BR (1) BRPI0710122A2 (zh)
CA (1) CA2645171A1 (zh)
MX (1) MX2008012662A (zh)
RU (1) RU2008143219A (zh)
TW (1) TW200806284A (zh)
WO (1) WO2007118009A1 (zh)
ZA (1) ZA200807828B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102652605B1 (ko) 2017-08-27 2024-03-28 로드스 테크놀로지즈 안과 질환 치료를 위한 약학제적 조성물
EP3698797A1 (en) 2017-10-16 2020-08-26 Tsinghua University Mevalonic acid pathway inhibitor and pharmaceutical composition thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US6627610B1 (en) * 1992-05-29 2003-09-30 Jeffrey Glenn Method for inhibition of viral morphogenesis
US5578477A (en) * 1993-01-05 1996-11-26 Arch Development Corporation Identification and characterization of inhibtors of protein farnesyltransferase
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US5834434A (en) * 1993-05-18 1998-11-10 University Of Pittsburgh Inhibitors of farnesyltransferase
US5602098A (en) * 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
US6011175A (en) * 1993-05-18 2000-01-04 University Of Pittsburgh Inhibition of farnesyltransferase
US5965539A (en) * 1993-05-18 1999-10-12 Univeristy Of Pittsburgh Inhibitors of prenyl transferases
US5705686A (en) * 1993-05-18 1998-01-06 University Of Pittsburgh Inhibition of farnesyl transferase
US5458883A (en) * 1994-01-12 1995-10-17 Duke University Method of treating disorders of the eye
US5789558A (en) * 1994-01-31 1998-08-04 Merck & Co., Inc. Protein prenyltransferase
US5631401A (en) * 1994-02-09 1997-05-20 Abbott Laboratories Inhibitors of protein farnesyltransferase and squalene synthase
US5430055A (en) * 1994-04-08 1995-07-04 Pfizer Inc. Inhibitor of squalene synthase
DK0677513T3 (da) * 1994-04-15 2000-03-27 Takeda Chemical Industries Ltd Octahydro-2-naphthalencarboxylsyrederivat, dets fremstilling og anvendelse
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
US5571835A (en) * 1994-09-29 1996-11-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5585359A (en) * 1994-09-29 1996-12-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5831115A (en) * 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
ATE302613T1 (de) * 1995-08-09 2005-09-15 Banyu Pharma Co Ltd Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6693123B2 (en) * 1995-11-06 2004-02-17 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6204293B1 (en) * 1995-11-06 2001-03-20 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
US6310095B1 (en) * 1995-11-06 2001-10-30 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
AU7985698A (en) * 1997-06-19 1999-01-04 Johns Hopkins University, The Methods for treatment of ocular neovascularization
US7262338B2 (en) * 1998-11-13 2007-08-28 Performance Plants, Inc. Stress tolerance and delayed senescence in plants
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
BR9916566A (pt) * 1999-01-21 2001-11-13 Bristol Myers Squibb Co Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6436972B1 (en) * 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
EP1276726A2 (en) * 2000-04-27 2003-01-22 Abbott Laboratories Substituted phenyl farnesyltransferase inhibitors
US20020019527A1 (en) * 2000-04-27 2002-02-14 Wei-Bo Wang Substituted phenyl farnesyltransferase inhibitors
WO2001089584A2 (en) * 2000-05-23 2001-11-29 Amersham Health As Contrast agents
WO2002004677A2 (en) * 2000-07-06 2002-01-17 The Regents Of The University Of California Methods for diagnosis and treatment of psychiatric disorders
US7211595B2 (en) * 2000-11-30 2007-05-01 Abbott Laboratories Farnesyltransferase inhibitors
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
US7238514B2 (en) * 2001-01-05 2007-07-03 William Marsh Rice University Diterpene-producing unicellular organism
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
AU2002310441A1 (en) * 2001-06-14 2003-01-02 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
MXPA04004882A (es) * 2001-11-23 2005-04-11 Chugai Pharmaceutical Co Ltd Metodo para la identificacion de enzimas que tienen como objetivo tumores.
US20030199544A1 (en) * 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
US20030199542A1 (en) * 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
US20030216441A1 (en) * 2002-05-10 2003-11-20 Gwaltney Stephen L. Farnesyltransferase inhibitors
WO2004091660A1 (ja) * 2003-04-17 2004-10-28 Kowa Co., Ltd. Lklf/klf2遺伝子発現促進剤
JP2005073550A (ja) * 2003-08-29 2005-03-24 Toyota Motor Corp プレニルアルコールの製造方法
WO2005051392A1 (en) * 2003-11-20 2005-06-09 Children's Hospital Medical Center Gtpase inhibitors and methods of use
AU2006239219A1 (en) * 2005-04-27 2006-11-02 University Of Florida Research Foundation, Inc. Materials and methods for enhanced degradation of mutant proteins associated with human disease

Also Published As

Publication number Publication date
EP2001457A1 (en) 2008-12-17
RU2008143219A (ru) 2010-05-10
US20120108632A1 (en) 2012-05-03
AU2007234903B2 (en) 2012-03-01
AR060186A1 (es) 2008-05-28
ZA200807828B (en) 2009-11-25
AU2007234903A1 (en) 2007-10-18
CN101410104A (zh) 2009-04-15
JP2009532377A (ja) 2009-09-10
BRPI0710122A2 (pt) 2011-08-02
CA2645171A1 (en) 2007-10-18
KR20080111092A (ko) 2008-12-22
US20070232675A1 (en) 2007-10-04
US20100120851A1 (en) 2010-05-13
WO2007118009A1 (en) 2007-10-18
MX2008012662A (es) 2008-10-13

Similar Documents

Publication Publication Date Title
MX2009005993A (es) Tratamiento para ojo seco.
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2005018677A3 (en) Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
WO2010126626A3 (en) Dual mechanism inhibitors for the treatment of disease
EP1880719A3 (en) Composition for prophylaxis or treatment of urinary system infection and method thereof
WO2007115289A8 (en) Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2007128526A3 (en) Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
WO2007095618A3 (en) Benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
TW200505507A (en) Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MY153669A (en) Ocular allergy treatments field of the invention
SG171602A1 (en) Use of antisecretory factors for treating intraocular hypertension
WO2004066979A3 (en) Sustained release device and method for ocular delivery of adrenergic agents
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2007127711A3 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
BR0017158A (pt) Agonistas de 5ht2 para controlar a iop e tratar o glaucoma
TW200806284A (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
SG160323A1 (en) Methods for controlling angiogenesis and cell proliferation
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2008055205A3 (en) Pai-1 binding modulators for the treatment of ocular disorders
AR069144A1 (es) Inhibidores del complemento c1q para la prevencion y el tratamiento del glaucoma
WO2007149543A3 (en) Scar treatment using protein phosphatase inhibitors